A new study has uncovered the mechanisms behind the progression of Huntington’s disease, a neurodegenerative disorder that affects an estimated 1 in 10,000 Americans.
Researchers at the Broad Institute of MIT and Harvard, Harvard Medical School, and McLean Hospital have found that Huntington’s disease is initiated by long somatic DNA-repeat expansions in specific brain cells--striatal projection neurons--that trigger cellular toxicity and death only after the threshold of toxicity is crossed.
The CAG repeat in the Huntingtin (HTT) gene has been known to cause the disease, but this study has revealed the damage only occurs decades later--shedding light on how Huntington’s disease manifests.
Researchers redesigned their understanding of the disease, which now entails identifying strategies to impede CAG-repeat expansion before it leads to cellular toxicity.
Scientists employed innovative technologies, including droplet single-cell RNA sequencing, to evaluate gene expression profiles alongside the CAG repeat lengths in individual neurons. This elucidated the specific pathways that lead to cell dysfunction and death, marking a significant step forward in the precision of molecular neuroscience.
The research team analyzed over 500,000 individual cells from both Huntington’s patients and healthy controls and discovered that many neuron types express a broad spectrum of CAG repeats inherited but remain asymptomatic until much later in life.
The identification of viable molecular targets may lead to breakthroughs that can significantly alter the course of treatment and potentially prevent the onset of the disease altogether.
The Huntington’s disease paradigm shift could revolutionize neurodegenerative disease treatment by broadening target opportunities, from HTT only to CAG-repeat expansion.
The study stresses the importance of continued exploration and reimagining of disease mechanisms, which have the potential for wide-reaching applications, promising hope for families afflicted by similar genetic disorders.
The research conducted emphasizes a new era of inquiry in genetics, molecular biology, and neurology convergence to tackle complex genetic afflictions.